A detailed history of Vanguard Group Inc transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 4,774,483 shares of DAWN stock, worth $63.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,774,483
Previous 4,769,746 0.1%
Holding current value
$63.4 Million
Previous $69.6 Million 13.26%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$13.56 - $17.46 $64,233 - $82,708
4,737 Added 0.1%
4,774,483 $78.9 Million
Q4 2023

Feb 14, 2024

BUY
$9.68 - $15.37 $1.36 Million - $2.15 Million
139,992 Added 3.02%
4,769,746 $69.6 Million
Q3 2023

Nov 14, 2023

BUY
$11.22 - $14.86 $3.88 Million - $5.14 Million
346,090 Added 8.08%
4,629,754 $56.8 Million
Q2 2023

Aug 14, 2023

BUY
$11.74 - $14.47 $13.5 Million - $16.7 Million
1,151,683 Added 36.77%
4,283,664 $51.1 Million
Q1 2023

May 15, 2023

BUY
$12.75 - $23.41 $293,352 - $538,617
23,008 Added 0.74%
3,131,981 $41.9 Million
Q4 2022

Feb 10, 2023

BUY
$18.77 - $22.0 $9.26 Million - $10.9 Million
493,532 Added 18.87%
3,108,973 $66.9 Million
Q3 2022

Nov 14, 2022

SELL
$16.44 - $26.57 $181,382 - $293,146
-11,033 Reduced 0.42%
2,615,441 $52.4 Million
Q2 2022

Aug 12, 2022

SELL
$5.72 - $17.9 $2.06 Million - $6.44 Million
-359,952 Reduced 12.05%
2,626,474 $47 Million
Q1 2022

May 13, 2022

SELL
$9.12 - $17.47 $440,961 - $844,691
-48,351 Reduced 1.59%
2,986,426 $29.6 Million
Q4 2021

Feb 14, 2022

BUY
$15.65 - $26.33 $34.7 Million - $58.3 Million
2,214,704 Added 270.06%
3,034,777 $51.1 Million
Q3 2021

Nov 12, 2021

BUY
$20.0 - $27.92 $4.01 Million - $5.6 Million
200,689 Added 32.4%
820,073 $19.5 Million
Q2 2021

Aug 13, 2021

BUY
$19.0 - $23.69 $11.8 Million - $14.7 Million
619,384 New
619,384 $14.1 Million

Others Institutions Holding DAWN

About Day One Biopharmaceuticals, Inc.


  • Ticker DAWN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 73,461,104
  • Market Cap $975M
  • Description
  • Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...
More about DAWN
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.